ACE2 Deficiency Modifies Renoprotection Afforded by ACE Inhibition in Experimental Diabetes
Diabetes2008Vol. 57(4), pp. 1018–1025
Citations Over TimeTop 10% of 2008 papers
Chris Tikellis, Katarzyna Bialkowski, Josepha Pete, Karen Sheehy, Su Qui, Colin I. Johnston, Mark E. Cooper, Merlin C. Thomas
Abstract
The expression of ACE2 is significantly modified by diabetes, which impacts both pathogenesis of kidney disease and responsiveness to RAS blockade. These data indicate that ACE2 is a complex and site-specific modulator of diabetic kidney disease.
Related Papers
- → Not All Angiotensin-Converting Enzyme Inhibitors Are Equal: Focus on Ramipril and Perindopril(2013)46 cited
- → Cross-over study comparing effects of treatment with an angiotensin converting enzyme inhibitor and an angiotensin II type 1 receptor antagonist on cardiovascular changes in hypertension(1998)15 cited
- → The ADVANCE trial – Authors' reply(2008)3 cited
- [Principles of choice of an angiotensin-converting enzyme inhibitor: specific features of perindopril].(2014)
- → Perindopril: world first launch in France for this ACE inhibitor(1989)